SCHEMBL3684432

SCHEMBL3684432

Cc1ccc(S(=O)(=O)n2ccc3c(C)cccc32)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.58
FABP4 P15090 2/20 0.56
KDM4E B2RXH2 1/20 0.54
UBE2N P61088 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.52
POLB P06746 1/20 0.52
ALDH3A1 P30838 1/20 0.52
HTT P42858 1/20 0.52
NOD1 Q9Y239 1/20 0.52
PPARG P37231 1/20 0.52
PPARD Q03181 1/20 0.52
PPARA Q07869 1/20 0.52
ALK Q9UM73 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
HTR1A P08908 2/20 0.48
DRD2 P14416 2/20 0.48
HTR2A P28223 1/20 0.48
HTR1D P28221 1/20 0.48
HTR1B P28222 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285388 1.00 HTR6 (0.58) HTR6FABP4KDM4EUBE2NL3MBTL1
SCHEMBL3621599 0.89 HTR6 (0.68) HTR6FABP4HTTPPARGPPARD
SCHEMBL30949526 0.85 HTR6 (0.59) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL4560894 0.85 HTR6 (0.56) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL11218072 0.85 HTR6 (0.59) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL30096985 0.85 HTR6 (0.56) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL6570590 0.85 HTR6 (0.76) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL10823230 0.85 HTR6 (0.56) HTR6FABP4KDM4EUBE2NL3MBTL1
SCHEMBL505125 0.85 HTR6 (0.56) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL30967914 0.82 HTR6 (0.54) HTR6KDM4EUBE2NL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813611-B1 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME KISSEI PHARMACEUTICAL (JP) 2014-10-01 EP disclosed
US-7750145-B2 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-07-06 US disclosed
US-20090074738-A1 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-03-19 US disclosed
EP-1813611-A1 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME Kissei Pharmaceutical Co., Ltd. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074738-A1 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME SLC5A1, SLC5A2, UGGT1 HTR6 1136/4885FABP4 266/4885KDM4E 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.